Daclatasvir: uses, dosage, safety, and treatment guidance

Daclatasvir is a direct-acting antiviral inhibitor of hepatitis C virus NS5A used to treat chronic hepatitis C infection as one component of a complete combination antiviral regimen in jurisdictions where it remains authorized. The active ingredient is daclatasvir, marketed in various regions under Daklinza and region-specific generic daclatasvir products.

• Indications: chronic hepatitis C genotypes covered by local approval, commonly in combination with sofosbuvir with or without ribavirin, selected by genotype, cirrhosis, transplant status, and previous treatment.
• Dosage: usually taken once daily with or without food, with dose adjustment for strong or moderate CYP3A inhibitors or inducers and duration determined by the full regimen.
• Contraindications: use with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, or St John’s wort, or hypersensitivity; companion-drug contraindications also apply.

What is Daclatasvir used for?

Daclatasvir is prescribed for carefully selected patients when its expected clinical benefit outweighs its condition-specific risks.

Chronic hepatitis C genotypes covered by local approval, commonly in combination with sofosbuvir with or without ribavirin, selected by genotype, cirrhosis, transplant status, and previous treatment. Diagnosis matters because similar symptoms can arise from conditions that need different treatment. A prescriber considers medical history, current medicines, examination findings, laboratory data, and treatment goals before choosing this drug.

How does Daclatasvir work?

It binds the viral NS5A protein and disrupts both replication-complex formation and assembly of hepatitis C virions. Its low barrier to resistance means it must be combined with other active antivirals.

The pharmacologic effect does not make the medicine suitable for every person with similar symptoms. Patients who plan to buy Daclatasvir should verify the diagnosis and prescription first, because Daclatasvir price cannot substitute for clinical selection, monitoring, or authentic supply.

How should Daclatasvir be taken or used?

Take at the same time daily and complete every component for the full prescribed duration. Do not use as monotherapy or change companion drugs independently. Confirm hepatitis B status before treatment because reactivation can occur.

Read the dispensing label every time, use the correct measuring or administration device, and never share prescription medicine. Contact the care team before changing the schedule, crushing a dosage form, switching formulations, or stopping long-term therapy.

Which Daclatasvir dosage variants are available?

Common marketed variants include 30 mg and 60 mg tablets; 90 mg tablets are available in selected markets for dose adjustment with interacting medicines.

Availability and licensed indications differ by country and manufacturer. When comparing where to buy Daclatasvir 30 mg and 60 mg tablets; 90 mg tablets are available in selected markets for dose adjustment with interacting medicines, confirm the precise strength, dosage form, route, and package directions rather than choosing by Daclatasvir price alone. Products with different release characteristics, concentrations, or routes may not be interchangeable.

What are the most common side effects of Daclatasvir?

The more frequently reported effects include headache, fatigue, nausea, insomnia, itching, weakness, and, when ribavirin is included, anemia and additional regimen-related effects.

Not every patient experiences these reactions, and their likelihood depends on dose, formulation, duration, health status, and other medicines. Record when symptoms begin and whether they follow a dose. Persistent, worsening, or function-limiting effects should be discussed rather than managed by an unapproved dose change.

Which serious effects require urgent medical care?

Slow heartbeat, fainting, severe weakness, jaundice, abdominal swelling, confusion, allergic swelling, or return of hepatitis symptoms requires urgent review. Amiodarone with sofosbuvir-containing therapy can cause life-threatening bradycardia.

Emergency warning signs should not be watched at home while waiting for the next routine appointment. Bring the medication package and a current medicine list when seeking urgent help so clinicians can identify the active ingredient, strength, and possible interaction.

Which medicines and substances interact with Daclatasvir?

Rifampin, carbamazepine, phenytoin, and St John’s wort are contraindicated because they lower exposure. Clarithromycin, azole antifungals, ritonavir, efavirenz, etravirine, nevirapine, digoxin, dabigatran, and some statins may require avoidance, adjustment, or monitoring.

Give the prescriber and pharmacist a complete list of prescription drugs, nonprescription products, vitamins, supplements, and recreational substances. Interaction risk can arise when another drug is started, stopped, or dose-adjusted, even after a stable period on treatment.

Can Daclatasvir be used with alcohol?

Alcohol advice depends on the indication, formulation, organ function, and other medicines, so an individualized recommendation is safer than assuming that moderate use is harmless.

Alcohol may worsen dizziness, sedation, dehydration, low blood pressure, impaired glucose control, gastrointestinal irritation, or liver stress where those effects are relevant. Avoid alcohol when the prescriber or product information advises it, and never drive when treatment or alcohol impairs alertness.

Is Daclatasvir safe during pregnancy or breastfeeding?

Daclatasvir pregnancy data are limited. If ribavirin is included, strict pregnancy avoidance applies to patients and partners during treatment and for the specified period afterward; breastfeeding advice depends on every regimen component.

Tell the prescriber about pregnancy plans, a positive test, breastfeeding, or fertility concerns before treatment whenever possible. Exposure decisions should consider gestational timing, dose, route, untreated disease, safer alternatives, and infant factors.

What monitoring is needed during Daclatasvir treatment?

Confirm hepatitis C RNA, genotype and resistance factors when relevant, cirrhosis or transplant status, hepatitis B markers, liver and kidney function, complete blood count when warranted, adherence, interactions, and sustained virologic response after therapy.

Keep scheduled reviews and report new symptoms between visits. Monitoring is intended to detect loss of effectiveness, organ toxicity, interaction effects, and the need for dose adjustment before a preventable complication becomes severe.

What should be done after a missed dose or overdose?

Follow the locally approved missed-dose window and never double. Overdose has no specific antidote and requires observation and supportive care, with attention to the complete antiviral regimen.

Do not induce vomiting or improvise a corrective dose. Exact advice depends on the amount, time, formulation, symptoms, age, and medical history, so provide those details promptly to a poison center or emergency clinician.

How should Daclatasvir be stored and obtained?

Store tablets in their original package at labeled room temperature protected from moisture and excessive heat. Because authorization varies by country, retain packaging that identifies the manufacturer, strength, and expiry.

Before deciding to buy Daclatasvir, confirm the authorized dosage form, intact packaging, expiration date, and required monitoring. Daclatasvir price should remain secondary to prescription accuracy, storage integrity, and licensed dispensing.

People who buy Daclatasvir should use a licensed pharmacy and contact a qualified clinician if the supplied product differs from the prescription or expected appearance.

Medical information disclaimer

This page provides general education and does not replace diagnosis, prescribing, monitoring, or emergency care. Follow the instructions supplied by the treating clinician and the medicine’s approved local labeling.